Eli Lilly agreed to acquire AtaiBeckley in a deal valued at $2.8 billion upfront, with potential total consideration rising to about $3.8 billion tied to development and regulatory milestones. The acquisition expands Lilly’s neuroscience footprint via AtaiBeckley’s psychedelic-based psychiatry program, led by intranasal BPL-003 (mebufotenin benzoate) for treatment-resistant depression. The transaction follows a string of Lilly deals enabled by its cash generation and reinforces big pharma’s renewed interest in psychedelic-era assets as regulatory frameworks evolve. Market attention will now focus on the clinical durability of AtaiBeckley’s lead program and the risk profile as it advances in pivotal settings. For biotech investors, the purchase is another example of capital flowing from large-cap pharma toward late-stage neuroscience adjacencies—with strategic fit increasingly driving pricing beyond pure pipeline novelty.